4D Molecular Therapeutics (4DMT) is a clinical-stage gene therapy company pioneering the development of next-generation, customized AAV vectors and product candidates. Utilizing its proprietary Therapeutic Vector Evolution platform, 4DMT aims to unlock the full potential of gene therapy for both rare and large market diseases by designing vectors that can be precisely targeted to specific tissues and overcome existing limitations of AAV technology. Their research focuses on ophthalmology, cardiology, and pulmonology, with a pipeline of innovative product candidates advancing through clinical trials. The company is committed to inventing and developing transformative genetic medicines to address unmet medical needs.
Serves as the company's primary hub for executive leadership, corporate operations, research and development (R&D), process development, and quality control for its gene therapy candidates.
Includes advanced research and development laboratories, process development labs, quality control facilities, and collaborative office spaces designed to foster innovation in gene therapy. The company also operates a nearby cGMP manufacturing facility.
A dynamic, science-driven environment focused on innovation, collaboration, and a patient-centric approach. Emphasizes scientific rigor, teamwork, and a commitment to developing transformative genetic medicines in a fast-paced biotech setting.
Strategically located in the San Francisco Bay Area biotech hub, providing access to a rich talent pool, leading research institutions, and a vibrant ecosystem for life sciences. This location is central to 4DMT's mission of advancing its pipeline of targeted AAV gene therapies.
4D Molecular Therapeutics' core operations, including research, development, and manufacturing, are primarily centered in Emeryville, California, USA. While its physical operational footprint is U.S.-based, the company's impact is global. It conducts clinical trials that may involve international sites and aims to develop therapies for diseases affecting patient populations worldwide. Strategic collaborations and partnerships can also extend its reach and activities on an international scale.
5858 Horton Street, Suite 455
Emeryville
California
USA
Address: An additional cGMP manufacturing facility in Emeryville, CA (separate from the main headquarters building).
Supports the company's R&D pipeline by providing in-house manufacturing capabilities for its AAV-based therapeutics. This ensures robust quality control and the ability to scale up production for clinical trials and eventual commercialization, leveraging the Bay Area's biotech infrastructure.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, 4D Molecular Therapeutics' leadership includes:
4D Molecular Therapeutics has been backed by several prominent investors over the years, including:
In the past 12 months, 4D Molecular Therapeutics has strengthened its leadership team with key appointments, including a new Chief Financial Officer and a new Chief Medical Officer, alongside an internal promotion to Chief Development Officer. No major C-suite departures were publicly announced during this period.
Discover the tools 4D Molecular Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for 4D Molecular Therapeutics likely use the company's domain, 4dmt.com. Standard patterns include [first_initial][last] or [first].[last]. For example, an employee named Jane Doe might have an email address like jdoe@4dmt.com.
[first_initial][last]@4dmt.com
Format
jdoe@4dmt.com
Example
80%
Success rate
4DMT Press Release • February 28, 2024
4DMT announced its financial results for Q4 and full year 2023, highlighting progress in its clinical programs, including 4D-150 for wet AMD and DME, and outlined upcoming milestones for its pipeline....more
4DMT Press Release • February 8, 2024
4D Molecular Therapeutics shared encouraging interim results from the Phase 2 PRISM trial for its gene therapy candidate 4D-150, showing significant clinical activity and a favorable safety profile in patients with wet AMD, a leading cause of vision loss....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including 4D Molecular Therapeutics, are just a search away.